New hope to halt devastating lung damage in young transplant patients
NCT ID NCT04908735
Summary
This study is testing if adding the drug ruxolitinib to standard steroid treatment can reverse early signs of lung damage in children and adults who have had a stem cell transplant. The goal is to stop the progression to a severe, often fatal lung condition called bronchiolitis obliterans (BO) before it becomes permanent. Researchers will measure lung function improvement in a small group of 7 participants to see if this approach is effective.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States
Conditions
Explore the condition pages connected to this study.